Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: European Society of Hypertension and Chinese Hypertension League Stroke in Hypertension Optimal Treatment Trial
Brief Summary: Stroke is one of the major causes not only of mortality, but of disease burden worldwide, because of residual disability and cognitive decline. Although blood pressure lowering has been clearly shown to be the most effective means for primary and secondary prevention of stroke, the systolic blood pressure (SBP) levels to achieve by treatment in order to optimize prevention results are unknown, and whether SBP levels lower than those usually recommended are accompanied by further or reduced benefits is undecided yet. Likewise, while low-density lipoprotein cholesterol (LDL-C) lowering by statins has been shown to be associated with primary and secondary stroke prevention, whether more intense lowering is or is not of further benefit is unknown. The Stroke in Hypertension Optimal Treatment Trial (ESH-CHL-SHOT) is a factorial 3 x 2 arm, multicenter, randomized clinical trial designed to test the hypothesis that in elderly patients at high risk of recurrent stroke (previous recent stroke or TIA) antihypertensive treatment programs aimed at reducing SBP to the usually recommended values (\< 145 to 135 mmHg), to a lower goal (\< 135 to 125 mmHg) or to even lower values (\< 125 mmHg) will result in progressively greater reductions in recurrent stroke, incidence of cardiovascular outcomes and cognitive decline. Parallely, the preventive efficacy of more and less intense LDL-C reductions will be tested on the same outcomes.


Options:
A: Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: lisinopril, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: HCTZ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrochlorothiazide | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): HCTZ | Intervention Type: DRUG; Name: nifedipine, long acting; Assigned to Arm(s): Candesartan, Lisinopril | Intervention Type: DRUG; Name: metoprolol, long-acting; Assigned to Arm(s): Candesartan, Lisinopril
B: Arm Label: SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: OTHER; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Arm Label: SBP < 125 mmHg and LDL-C < 1.8 mmol/l; Type: ACTIVE_COMPARATOR; Interventions: Drug: all approved antihypertensive drugs; all approved statins | Intervention Type: DRUG; Name: all approved antihypertensive drugs; all approved statins; Assigned to Arm(s): SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 125 mmHg and LDL-C < 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l, SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l
C: Arm Label: Aerobic Exercise (Ex); Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Training, Other: Usual Care | Arm Label: Intensive Reduction of Vascular Risk Factors (IRVR); Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Stretching Exercise | Arm Label: IRVR+Ex; Type: EXPERIMENTAL; Interventions: Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Behavioral: Aerobic Exercise Training | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual Care, Behavioral: Stretching Exercise | Intervention Type: DRUG; Name: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine); Assigned to Arm(s): IRVR+Ex, Intensive Reduction of Vascular Risk Factors (IRVR) | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Aerobic Exercise (Ex), IRVR+Ex | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Aerobic Exercise (Ex), Usual Care | Intervention Type: BEHAVIORAL; Name: Stretching Exercise; Assigned to Arm(s): Intensive Reduction of Vascular Risk Factors (IRVR), Usual Care
D: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo

Answer: B